Matthew Taylor

Father | Husband | Driver | Adventurer | Investor | Philanthropist | #FortyUnder40 winner | Lachman Consultants @LachmanConsult

[Lachman Consultants @LachmanConsult]

READ: Mastering Drug Product Remediation: 5 Essential Principles Post FDA Action
https://t.co/DnOQBUNvPt

"...navigating the intricate landscape of facility and Quality Management System (QMS) remediation following FDA enforcement actions demands precision, foresight, and a commitment to sustainable change." Click to Read More!

#FDA #Compliance #Remediation #Inspections #Manufacturing #Generics #Biologics #MedicalDevices

[Dr. Robert M. Califf @DrCaliff_FDA]

I enjoyed spending time at FDLI this year once again. In today’s fireside chat, I talked about FDA’s priorities, the amazing advance of technology that requires us to continue to evolve at FDA and our many efforts to help improve public health.

[Lachman Consultants @LachmanConsult]

We’ll see you at the #FDLI2024 Annual Conference. This 75th Anniversary celebration is scheduled for May 15-16 in Washington, DC. To set up an in-person meeting with our team at the conference, learn more about our #ExpertWitnessServices, & register for the event: https://t.co/AFAkw4iHCx

@foodanddruglaw
#foodanddrug #pharmaceuticals #drugmanufacturing #pharmaconsulting

[Lachman Consultants @LachmanConsult]

Lachman Consultant Services is in the house! Come visit our booth and we can talk #compliance, #regulatoryaffairs, #AI, #dataintegrity, or how great things are going so far here in Long Beach at #PDAweek!

#quality #gmp #annex1 #PDAannual @PDAonline

[Matthew Taylor @mtaylord]

On my way into NYC for #DCAT, DM me to meet this afternoon or at the networking reception this evening.

#dcatweek

[Lachman Consultants @LachmanConsult]

READ: AI Laws on the Move
https://t.co/EiL0daPrGh

Is your firm preparing for the wave of AI regulations, laws, white papers, and regulatory guidances? As reported in a previous Lachman blog, EU Artificial Intelligence (AI) Act: Impact on Pharma and MedTech, laws are emerging, but can companies keep up with the pace?

#AI #ArtificialIntelligence #RegulatoryAffairs #FDA #Compliance #Generics #MedicalDevices #MedTech #BioTech

[AAM @AccessibleMeds]

What's Wrong With This Picture? "There needs to be a fix to this irrational [generic drug] pricing model." - Bob Pollock from Lachman Consultants @LachmanConsult

https://t.co/KmPCjzDycx

[Lachman Consultants @LachmanConsult]

We’re looking forward to seeing you at the #AAM #Access2024 annual meeting, JW Marriott, Tampa, Florida on February 5-7. You’re invited to visit with us at booth 11 & meet the #LachmanTeam. Book a meeting & Experience. Excellence.™ at the #AAMconference: https://t.co/jrC6xX0Wpv

[AAM @AccessibleMeds]

Join #Access2024 to connect with industry leaders and chart the future of #generics and #biosimilars. Attend professional networking opportunities and social events to advance your career.
📍February 5–7, 2023 | Tampa, FL
➡️ Register: https://t.co/g1Z3G8TXQF #ThrowbackThursday

[Lachman Consultants @LachmanConsult]

BLOG: Happy Thanksgiving Y’all!
https://t.co/MRLFkuVKgt

"I was trying to come up with something clever to say to put a smile on your faces, but I find it hard this year. So, I chose to develop a Thanksgiving library list to share with you that will hopefully bring a smile to your face." Click to Read More!

#thanksgiving #holidays #SilenceoftheYams

[Lachman Consultants @LachmanConsult]

Frances M. Zipp – Recipient of the Joseph X. Phillips Professional Achievement Award

https://t.co/WyRbzpA9op

Please join us in congratulating Fran for this prestigious award recognizing all that she continues to do for our industry!

#ISPE @ISPEorg

[Lachman Consultants @LachmanConsult]

Signs of Progress on the #Nitrosamine Front – Notes from the #Nitrosamines Session at #GRxBiosims 2023
https://t.co/ySzFijTIcK

#biosimilars #generics #regulatoryaffairs #grxbiosims2023

[Lachman Consultants @LachmanConsult]

We’re here at #GRxBiosims with @AccessibleMeds, come say hello!

[Kristin Willemsen @kwistin093]

Interesting fireside chat with @DrCaliff_FDA and @AccessibleMeds on the importance of a resilient #generic and #biosimilars industry to ensure access for patients #GRxBiosims

[Matthew Taylor @mtaylord]

I'll be there! Will you?

[PDA @PDAonline]

See you in DC! With more than 40 FDA experts participating as speakers and panelists, #PDAFDA is the place to be 18-20 Sept. for the latest on important issues related to CGMP and quality assurance. Livestream option also available! https://t.co/4yQsyfVw0B

[Lachman Consultants @LachmanConsult]

BLOG: 5 Reasons Why You Should Perform a Mock Inspection Now

https://t.co/XC8Pu9vgPw

"Whether you’re overseas or right here at home in the U.S., FDA regulatory oversight is rigorous, particularly after COVID19 now that the FDA has aggressively resumed on-the-ground inspections..." Click to Read More

#Generics #Biologics #MedicalDevices #FDA #Inspections

[Lachman Consultants @LachmanConsult]

LATEST NEWS: NDSRIs – Alignment At Last (Sort Of)

"The industry as a whole rejoiced on Friday with the publication of the new NDSRI guidance from the FDA, previously discussed here. Now that we all have had more time to carefully read and absorb the details posted by the FDA in the guidance and on the corresponding webpage, many will discover that there are still a few discrepancies from other health authorities as well as a new call to action for manufacturers and application holders in the U.S."  READ MORE...

https://t.co/kUbe0O8KhR

#NDSRI #Nitrosamines #Compliance #FDA #ANDA #OTC #NDA

[Lachman Consultants @LachmanConsult]

READ: Risk Meets Data Governance in the Supply Chain 

https://t.co/xfYPDLURnW

#dataintegrity #datagovernance #supplychainresilience

[Lachman Consultants @LachmanConsult]

READ: New Guidance for Industry- Acceptable Intake Limits for NDSRIs and a New Webpage from FDA

https://t.co/PRF642rgGt

#NDSRI #FDA #Nitrosamines #pharmaceuticalmanufacturing #RegulatoryAffairs #CGMP #Biologics

[Matthew Taylor @mtaylord]

Check out my activity on Strava: https://t.co/YwOaYp7eax